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Abstract
Background: Cisplatin (cis-diamminedichloroplatinum II, CDDP) is one of the most effective chemotherapeutic
agents. However, its clinical use is limited due to the severe side effects, including nephrotoxicity and acute kidney
injury (AKI) which develop due to renal accumulation and biotransformation of CDDP. The alleviation or prevention
of CDDP-caused nephrotoxicity is currently accomplished by hydration, magnesium supplementation or mannitol-
induced forced diuresis which is considered for high-dose CDDP-treated patients. However, mannitol treatment
causes over-diuresis and consequent dehydration in CDDP-treated patients, indicating an urgent need for the
clinical use of safe and efficacious renoprotective drug as an additive therapy for high dose CDDP-treated patients.
Main body: In this review article we describe in detail signaling pathways involved in CDDP-induced apoptosis of
renal tubular cells, oxidative stress and inflammatory response in injured kidneys in order to pave the way for the
design of new therapeutic approaches that can minimize CDDP-induced nephrotoxicity. Most of these molecular
pathways are, at the same time, crucially involved in cytotoxic activity of CDDP against tumor cells and potential
alterations in their function might mitigate CDDP-induced anti-tumor effects.
Conclusion: Despite the fact that many molecules were designated as potential therapeutic targets for
renoprotection against CDDP, modulation of CDDP-induced nephrotoxicity still represents a balance on the knife
edge between renoprotection and tumor toxicity.
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Background
Cisplatin (cis-diamminedichloroplatinum II, CDDP) is one of
the most effective chemotherapeutic agents, widely used for
the treatment of several malignant diseases including head
and neck [1, 2], esophageal [3], bladder [4], testicular [5],
ovarian [6], uterine [7], cervical [8], breast [9], stomach [10],
non-small [11], and small-cell lung cancers [12]. CDDP
crosslinks purine bases within DNA and interferes with
DNA synthesis [13]. An impaired cell division is the main
CDDP-based effect and, accordingly, CDDP shows highest
activity in rapidly proliferating cells [13]. Therefore,
CDDP-induced mucosal injury in gastrointestinal tract as
well as myelosuppression due to the CDDP-caused injury of
bone marrow, are severe and life-threatening side effects of
CDDP-based therapy [14–17]. However, the most usually
observed, dose-dependent and cumulative CDDP-caused
side effect, noticed in 30–40% of patients, is nephrotoxicity
[18–22]. CDDP-induced nephrotoxicity is manifested as
acute kidney injury (AKI), salt or magnesium wasting and
loss of urinary concentrating ability [18–22]. CDDP-caused
renal dysfunction happens as a result of CDDP accumulation
and biotransformation in the kidneys [18–22]. The allevi-
ation or prevention of CDDP-caused nephrotoxicity is cur-
rently accomplished by short-duration and lower-volume
hydration, magnesium supplementation (8–16 milliequiva-
lents) or by mannitol-induced forced diuresis which is con-
sidered for high-dose CDDP-treated patients and/or patients
with preexisting hypertension [23]. However, mannitol
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treatment causes over-diuresis and consequent dehydration
in CDDP-treated patients, indicating an urgent need for the
clinical application of safe and efficacious renoprotective
drug, as an additive therapy for high dose CDDP-treated pa-
tients [24]. Until now, amifostine [(ethanethiol, 2-[(3-ami-
nopropyl)amino] dihydrogen phosphate ester)] was the
most commonly tested as nephroprotective agent against
CDDP, but several serious side effects, including ototox-
icity, hypotension, vertigo, hypocalciemia, severe nausea
and vomiting, limited its clinical use [25, 26]. Although
some of the other thiol-generating cytoprotective agents
(sodium thiosulfate, reduced glutathione and diethyl-
dithiocarbamate) appeared to reduce CDDP-caused
nephrotoxicity, all of them have demonstrated an un-
wanted tumor protecting effect which restricted their clin-
ical use [27, 28]. Consequently, there still remains an
unmet need for the development of new, renoprotoctive
agents in which activity should be relied on the modula-
tion of pharmacokinetics and biological effects of CDDP
in the kidneys. In this review paper, we emphasized
current knowledge regarding molecular and cellular
mechanisms involved in renal uptake, biotransformation
and toxicity of CDDP in order to pave the way for new
therapeutic approaches that can inhibit or minimize
CDDP-dependent nephrotoxicity.
Molecular mechanisms involved in renal uptake and
accumulation of CDDP
During glomerular filtration and tubular secretion,
CDDP accumulates in the kidneys [20]. Renal proximal
tubular epithelial cells (PTECs) absorb molecules from
primary urine and are mainly exposed to urinary ex-
creted xenobiotics [29]. Accordingly, CDDP concentra-
tion in PTECs is about five times greater than in the
blood [20]. Even non-toxic serum concentrations of
CDDP may reach toxic levels in the kidneys, resulting in
the development of renal dysfunction due to the severe
injury of S3 segment of proximal tubules [30, 31].
An important process mediating cellular accumulation of
CDDP is transporter-mediated uptake of this drug. Recent
public data identified several different membrane trans-
porters capable of transporting CDDP across the plasma
membrane and across PTECs: the organic cation transporter
2 (OCT2), the copper transporter 1 (Ctr1) and the multidrug
extrusion transporter 1 (MATE1) [32]. Among them, OCT2
is most important for renal uptake of CDDP while MATE 1
is mainly responsible for CDDP transportation from the
proximal tubule to the urine [22, 33]. OCT2 deficient mice
were protected from cisplatin-induced AKI due to the sig-
nificantly impaired renal uptake of CDDP while exacerbated
CDDP-caused nephrotoxicity, observed in MATE1 knockout
animals, was associated with notably reduced CDDP excre-
tion [22, 34, 35]. Additionally, gender differences in suscepti-
bility to CDDP-induced AKI and greater intensity of
CDDP-caused nephrotoxicity noticed in male rats, could be
explained by reduced OCT2 expression in PTECs of female
rats [36]. In line with these findings, notably reduced
CDDP-induced AKI was observed in patients with nonsy-
nonymous single-nucleotide polymorphism (SNP) in the
OCT2 gene (SLC22A2 (rs316019)) [37]. Hypomagnesiemia
provokes enhanced expression of OCT2 in PTECs resulting
in increased uptake of CDDP [38–41]. Findings obtained in
several clinical trials demonstrated that magnesium replace-
ment may down-regulate expression of OCT2 in PTECs
resulting in attenuation of CDDP-induced nephrotoxicity
[38–41]. Accordingly, magnesium supplementation (8–16
milliequivalents) is now, along with short-duration and
lower-volumn hydration, used for prevention of
CDDP-caused renal injury [23].
In similar manner, cimetidine, a pharmacological in-
hibitor of OCT2, prevents OCT2-dependent renal up-
take and toxicity of CDDP [41]. Katsuda and coworkers
demonstrated that continuous intravenous infusion of
cimetidine (20 μg/ml for 4 h) managed to efficiently pre-
vent CDDP-caused nephrotoxicity without influencing
anti-tumor activity of CDDP [41].
Interestingly, cimetidine-mediated inhibition of CDDP accu-
mulation was significantly enhanced in Ctr1-downregulated
PTECs, indicating synergistic effects of OCT2 and Ctr1 for
renal uptake of CDDP. Despite the fact that down-regulated
Ctr1 expression in PTECs significantly decreased their apop-
tosis and necrosis in vitro [42], the effects of Ctr1 deletion or
inhibition on the development of CDDP-induced AKI has not
yet been examined in vivo. Accordingly, future experimental
and clinical studies should be focused in exploring Ctr1 as a
molecular target for the enhancement of cimetidine-induced
attenuation of CDDP-caused-nephrotoxicity. Additionally, it is
important to highlight the fact that Ctr1 is localized on the
basolateral side of both proximal and distal tubular epithelial
cells. Accordingly, it was suggested that, in addition to its role
in CDDP renal uptake, Ctr1 might be, in similar manner as
MATE1, responsible for CDDP excretion [43]. In line with
these findings, it was recently reported by Chang and co-
workers that SNPs in SLC31A1/Ctr1 and SLC47A1/MATE1
genes were associated with increased urinary excretion of
well-known AKI biomarkers: kidney injury molecule-1
(KIM-1), calbindin, trefoil factor 3 (TFF3), cystatin C and
clusterin.
Extracellular biotransformation of CDDP begins immedi-
ately after transportation of CDDP to the apical surface of
renal epithelial cells. The initial step of CDDP-induced
nephrotoxicity is formation of glutathione conjugates in cir-
culation, mediated by glutathione-S-transferase. After enter-
ing the kidney, glutathione-conjugates are cleaved to
cysteinyl-glycine-conjugates by gamma glutamyl transpepti-
dase (GGT), which is expressed on the surface of PTECs.
Aminopeptidase N (APN) converts cysteinyl-glycine-conju-
gates into cysteine-conjugates which are, after entering into
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the PTECs, further metabolized to highly reactive and
nephrotoxic thiols by enzymic activity of cysteine-S-conju-
gate beta-lyase (CCBL) [22, 44]. Having in mind that, among
all tissues, GGT has the highest activity in the kidneys, par-
ticularly on the apical surface of PTECs, this enzyme was
considered as a potential target for the attenuation of
CDDP-induced nephrotoxicity. However, obtained results
are controversial, suggesting that enhanced GGT activity
may either increase or decrease sensitivity of PTECs to
CDDP [29]. More than two decades ago, Hanigan and col-
leagues demonstrated amelioration of CDDP-induced AKI
in rats pre-treated with acivicin, a non-competitive inhibitor
of GGT [45]. Additionally, the same research group showed
that CDDP-induced nephrotoxicity was dependent on GGT
activity and was not associated with CDDP renal uptake
[46]. GGT knockout animals did not develop CDDP-induced
AKI although there were no differences in CDDP accumula-
tion between PTECs of wild-type (WT) and GGT-deficient
mice [46]. Although findings obtained by Hanigan and col-
leagues strongly indicated an important role of GGT in toxi-
fication of CDDP, several other research groups showed
opposite results suggesting that GGT could be considered as
the main CDDP detoxification enzyme in the kidneys [47,
48]. Daubeuf and colleagues and Paolicchi and coworkers
demonstrated that GGT products (cysteinyl-glycine-conju-
gates) and the GGT substrate (glutathione) were able to co-
valently attach to CDDP rendering it non-toxic [47, 48].
Taken together, these, on first sight opposite findings, suggest
that GGT-mediated detoxification of CDDP was dependent
on the complex interactions between CDDP-derived metab-
olites and PTEC-expressing enzymes. Indeed, GGT is, along
with APN and CCBL, a member of multi-enzyme pathway
which capacity to convert xenobiotic-glutathione conjugates
to nephrotoxic metabolites is dependent on the synergistic
activity of these three enzymes [49]. In line with these obser-
vations, Hauscheer and colleagues proposed that BNP7787
(disodium 2,2-dithio-bis-ethane sulfonate, dimesna, Tavo-
cept™) could be considered as effective nephroprotective
agent for the prevention of CDDP-induced renal dysfunction
since BNP7787-derived mesna-disulfide heteroconjugates,
which contain a terminal gamma-glutamate moiety (mesna--
glutathione and mesna-cysteinyl-glutamate), simultanously
inhibited GGT, APN and CCBL activity, attenuated gener-
ation of highly potent and nephrotixic thiols and ameliorated
CDDP-induced nephrotoxicity [49, 50]. Similarly, due to
their capacity to prevent the formation of a
glutathione-cisplatin-conjugates, thiol agents have been
tested as nephroprotective drugs in CDDP-treated patients.
Among them, Amifosten was FDA-approved for the preven-
tion of AKI in CDDP-treated patients with non-small cell
lung cancer and advanced ovarian cancer [26]. Nevertheless,
renoprotective effects of Amifostine were not consistently
observed in CDDP-treated patients and many severe side ef-
fects including dysfunction of vestibulocochlear,
gastrointestinal and cardiovascular systems significantly lim-
ited its clinical use [25, 26]. Accordingly, several recently
conducted experimental and clinical trials focused their at-
tention in the modulation of intracellular signaling pathways
which were responsible for CDDP-induced cell cycle arrest
or cell death.
Molecular mechanisms responsible for CDDP-induced cell
cycle arrest or cell death
CDDP-induced nephrotoxicity is dose dependent and in-
volves necrosis, apoptosis and necroptosis of renal cells
[51–53]. In vitro studies revealed that necrotic cell death
is caused by high levels of CDDP, while apoptosis is
caused by lower concentrations of CDDP [51, 52]. Three
apoptotic pathways (extrinsic, intrinsic (mitochondrial) and
endoplasmic reticulum (ER) stress pathway) may be initiated
in PTECs after CDDP treatment. CDDP activates
caspase-3,-8 and− 9 and induces translocation of Bax to
mitochondria resulting in cytohrome c, apoptosis-inducing
factor (AIF), endonuclease G release [52–57]. Inhibition of
caspase-3 and caspase-9 suppressed CDDP-induced cell
death [57], while cytochrome c release was diminished in
CDDP-treated Bax-deficient mice [54], suggesting the im-
portant role of both extrinsic and intrinsic apoptotic path-
ways in the development of CDDP-induced AKI. In addition
to these two pathways, CDDP-induced apoptosis of PTECs
also involves the ER-stress pathway mediated by caspase 12
and calcium-independent phospholipase A2 (ER-iPLA2)
[58–60]. Inhibition of caspase 12 as well as suppression of
ER-iPLA2 significantly reduced apoptotic cell death of
CDDP-injured PTECs and ameliorated CDDP-caused
nephrotoxicity [58–60].
In addition to necrosis and apoptosis, necroptosis is
also observed in renal cells after CDDP treatment. Dele-
tion of genes involved in necroptotic pathway (receptor--
interacting protein 1 (RIP1) and mixed lineage kinase
domain-like protein (MLKL)) managed to protect ex-
perimental animals against CDDP-induced AKI [61, 62]
indicating that pharmacological inhibitors of these mole-
cules could be considered as possible therapeutic agents
for the attenuation of CDDP-caused nephrotoxicity.
CDDP treatment induces DNA damage, dysfunction of
cytoplasmatic organelles and oxidative stress in PTECs.
Once the cisplatin enters PTECs, its complex interac-
tions with the cellular environment convert it into a
positively charged electrophile that has a high affinity to
DNA [63]. This results in formation of intrastrand cross-
link between two adjacent guanine residues within DNA
[43]. More precisely, platinum atom of CDDP forms co-
valent bonds with N7 position of purine bases to form
1,2- or 1,3-intrastrand crosslinks and a lower percentage
of interstrand crosslinks. Formation of CDDP-induced
DNA adducts prevents DNA synthesis and replication
causing the cell to enter in cell-cycle arrest mode.
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Additionally, CDDP-caused crosslinks and disrupted
DNA structure resulting in the activation of DNA repair
mechanisms [43]. Among them, nucleotide excision re-
pair (NER) pathway is mainly responsible for the repair
of the CDDP-induced intrastrand adducts while base ex-
cision repair (BER), homologous recombination (HR),
and Fanconi anemia pathways are involved in the repair
of CDDP-caused interstrand cross-links [64]. Although
an increased activity of these DNA repair pathways has
been associated with alleviation of CDDP-induced AKI,
member proteins of these signaling cascades are not
considered as ideal molecular targets for prevention of
CDDP-caused nephrotoxicity since malignant cells also
used enhanced activity of NER, BER and HR systems for
resistance to CDDP [65].
Among cellular organelles, ER and mitochondria are the
most severe injured by CDDP (Fig. 1) [43]. CDDP-caused al-
terations in translation lead to the accumulation of misfolded
proteins within ER, resulting in the development of ER
stress. At the same time, positively charged CDDP electro-
phile preferentially accumulate in the negatively charged
mitochondria affecting their function [66]. Mitochondrial
dysfunction and consequent reduced ATP synthesis force
CDDP-injured PTECs to function in a starvation mode.
Thus, CDDP-induced prolonged ER stress and hypoxic in-
jury provoke caspase-mediated apoptosis or induce extensive
production of free radicals and reactive oxygen species
(ROS) resulting in the development of oxidative stress [43].
In addition to mitochondrial dysfunction, CDDP may pro-
voke oxidative stress in PTECs by inducing ROS formation
in the microsomes through the activation of cytochrome
P450 system [20, 67]. Administration of antioxidants (vita-
mins C, E, selenium, alpha lipoic acid, dimethylthiourea
(DMTU)) showed beneficial, renoprotective effects against
CDDP-caused nephrotoxicity [68–71], confirming the im-
portant pathogenic role of oxidative stress in the develop-
ment of CDDP-induced AKI. Since DMTU significantly
suppressed p53 activation in CDDP-injured cells, p53 was
considered as important downstream target of CDDP-gener-
ated ROS.
Several lines of evidence confirmed that P53 protein was
critically involved in the development of CDDP-induced
Fig. 1 P53 signaling pathways leading to tubular cell apoptosis after cisplatin treatment. By transcriptional regulation, nuclear p53 may activate
proapoptotic genes, such as PUMA-α, caspases, PIDD, and ER-iPLA2, may suppress antiapoptotic genes, including p21 and TauT. In the absence of
transcription, p53 may induce apoptosis via interactions with Bcl-2 family proteins in mitochondria and/or cytosol. Abbreviations: Bcl-2: B-cell
lymphoma 2; Bcl-xL: B-cell lymphoma-extra large; Bax: Bcl-2-associated X protein; Bak: Bcl-2 homologous antagonist killer; PUMA-α: p53
upregulated modulator of apoptosis; PIDD: p53-induced protein with a death domain; ER-iPLA2: Ca2+-independent phospholipase A2; Cdk2:
Cyclin-dependent kinase complex; TauT: taurine transporter
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nephrotoxicity [72]. CDDP treatment provokes increased ex-
pression and activation of p53 in injured kidneys where p53
regulates apoptosis of PTECs through transcriptional activa-
tion and repression of genes whose promoters contain
p53-binding sites (Fig. 1) [72]. CDDP-caused alterations in
DNA structure activates molecular sensors for DNA dam-
age: ataxia telangiectasia (ATM) and Rad3-related (ATR)
proteins, which activate Checkpoint kinase 2 (Chk2), result-
ing in phosphorylation and activation of p53 [65, 72].
P53-up-regulated modulator of apoptosis (PUMA)- ,
p53-induced protein with death domain (PIDD), caspases 6
and 7, p21 protein and Taurine transporter (TauT) have the
most prominent role in p53-dependent modulation of
CDDP-induced acute renal failure. Activated p53 protein in-
duces increased accumulation of PUMA- in mitochondria
of CDDP-injured tubular cells where this protein interacts
with Bcl-xL. An enhanced PUMA- :Bcl-xL crosstalk en-
ables Bax-mediated permeabilization of mitochondrial mem-
brane and consequent release of cytochrome c, resulting in
caspase activation and apoptosis of renal tubular cells [73].
Accordingly, reduced induction of PUMA- was observed
in p53 deficient animals which were protected against
CDDP-induced nephrotoxicity [73], indicating the import-
ance of p53-dependent activation of PUMA- for apoptosis
of PTECs. In similar manner, p53 promotes translation of
PIDD which, through the activation of caspase 2, induces
mitochondrial release of AIF leading to the chromatin con-
densation and programmed cell death of CDDP-injured
PTECs [55]. In vitro and in vivo studies revealed important
role of p53 for caspase 6 and 7-dependent apoptosis of
CDDP-injured PTECs. Pharmacological inhibition as well as
genetic deletion of p53 blocked the activation of both execu-
tioner caspases and protected PTECs from CDDP-caused
apoptosis resulting in alleviation of CDDP-induced nephro-
toxicity [74].
Although induction of pro-apoptotic molecules is dom-
inant effect of p53 activation in CDDP-injured PTECs,
p53 interferes with anti-apoptotic molecules (p21 and
TauT) regulating their renoprotective function, as well.
P53-induces down-regulated expression of TauT gene and,
consequently, increases apoptosis in CDDP-injured renal
cells [75]. Similarly, p53 may regulate activity of p21 pro-
tein, a well-known anti apoptotic regulator of cell survival
[72]. Induction of p21 protein in renal cells is considered
as an important renoprotective mechanism against
CDDP-caused nephrotoxicity since both genetic deletion
or pharmacological inhibition of p21 significantly aug-
mented CDDP-provoked injury of PTECs [76, 77]. Mech-
anistically, p21-mediated inhibition of cyclin-dependent
kinase 2 (CDK2) was mainly responsible for
p21-dependent nephroprotection [78]. Having in mind
that CDDP-induced toxicity depends on CDK2 activity,
and that CDK2 inhibition protected kidney cells from
CDDP-induced cell death [79, 80], p21-dependent
suppression of CDK2 could be used as potentially useful
therapeutic approach for attenuation of CDDP-induced
AKI.
In addition to the regulation of apoptosis, p53 may con-
tribute to the development of CDDP-caused nephrotoxicity
by modulating autophagy which, as an adaptive mechanism,
promotes PTECs survival during AKI [72, 81]. Immediately
after exposure of PTECs to CDDP, markers of autophagy
(Beclin 1, Microtubule-associated proteins 1A/1B light chain
3B (LC3), and Autophagy-related protein 5 (Atg5)) were sig-
nificantly increased in CDDP-injured renal cells, indicating
development of autophagy [82]. Accordingly, inhibition of
autophagy in CDDP-treated animals resulted in increased
apoptotic cell death of PTECs [83]. Similarly, an increased
DNA damage and an enhanced p53 activation were ob-
served in PTECs of mice that lack autophagy related genes,
confirming capacity of p53 to regulate renoprotective au-
tophagy in CDDP-injured PTECs [82, 84, 85]. In
CDDP-injured PTECs, CDDP activates AMP-activated pro-
tein kinase (AMPK), a signaling molecule that regulates au-
tophagic protection against CDDP-induced AKI [81].
Accordingly, genetic deletion or pharmacological inhibition
of AMPK resulted in repressed autophagy in CDDP-injured
PTECs, followed by increased DNA damage and conse-
quently enhanced activation of p53. Having in mind that p53
regulates autophagy by inactivating mammalian target of
rapamycin (mTOR) pathway via AMPK, p53-based modula-
tion of AMPK activity could be considered as an important
mechanism for p53-dependent regulation of CDDP-induced
AKI [81].
P53 regulates activation of pro-apoptotic microRNA
(miR)-375 and cytoprotective miR-34a in CDDP-injured
PTECs [86]. Upon CDDP administration, p53 and nu-
clear transcription factor-kappa B (NF-κB) collabora-
tively induce enhanced expression of miR-375 which
suppressed activation of nephroprotective hepatocyte
nuclear factor 1 homeobox B (HNF-1β), resulting in
renal tubular cell apoptosis and nephrotoxicity. Add-
itionally, pharmacological inhibition of p53 or NF-κB re-
sulted in down-regulated expression of miR-375 which
led to the alleviation of CDDP-induced AKI. In contrast
to miR-375, inhibition of miR-34a induced increased
apoptosis of PTECs while enhanced expression of
miR-34a promoted survival of CDDP-injured PTECs, in-
dicating an important cytoprotective role of miR-34a in
CDDP-induced nephrotoxicity [87].
Based on all these findings, p53 represents potential
molecular target for alleviation of CDDP-caused nepro-
toxicity. Experimental studies already demonstrated that
temporary and reversible p53 suppression during cancer
therapy can be relatively safe [88]. Additionally, selective,
pharmacological inhibitors of p53 may be specifically de-
livered to renal cells without affecting primary tumor or
metastatic lesions [89, 90]. Accordingly, p53 antagonists
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could protect PTECs from CDDP-caused injury without
affecting CDDP-induced anti-tumor effects in malignant
cells. Furthermore, in some tumors p53 protein was re-
sponsible for tumor resistance to chemotherapeutics
[81]. In these patients, systemic administration of p53
antagonists may result in nephroprotection and at the
same time could sensitize malignant cells to anticancer
drugs promoting their therapeutic efficacy [91]. Despite
these promising expectations, it should be highlighted
that due to the complex role that p53 has in regulation
of cell survival, nephroprotection due to the selective
p53 renal inhibition should be investigated, in detail, in
CDDP-treated tumor-bearing animal models before it
will be considered as one of possible therapeutic ap-
proaches for CDDP-treated patients.
Signaling pathways responsible for extensive production
of inflammatory cytokines in CDDP-injured kidneys
CDDP-induced activation of NF-κB, poly ADP-ribose
polymerase-1 (PARP-1) and toll-like receptors (TLRs) path-
ways in PTECs and renal-infiltrated immune cells results in
extensive production of inflammatory cytokines [92]. CDDP
induces the phosphorylation and subsequent translocation of
NF-κB to the nucleus, where activated NF-κB promotes
transcription of tumor necrosis factor alpha (TNF-α) and
other inflammatory cytokines (IL-1, IL-6, IL-18) [93]. Simi-
larly, CDDP-induced DNA damage results in activation of
PARP-1 which promotes apoptosis of CDDP-injured PTECs
or induces up-regulation of TNF-alpha, IL-1 and IL-6 genes
contributing to the development of AKI [94]. Genetic dele-
tion of PARP-1 completely diminished CDDP-caused renal
injury and inflammation, while administration of selective,
pharmacological inhibitor of PARP-1 (PJ-34) efficiently pro-
tected against CDDP-induced nephrotoxicity [94, 95].
Several lines of evidence demonstrated that activation of
TLR-4, TLR-2 and TLR-9 may modulate CDDP-induced
acute renal injury and inflammation [96, 97]. Animals de-
ficient in TLR-4 showed lower serum levels of TNF-α and
were protected from CDDP induced renal toxicity [98].
Activation of TLR-4 on renal parenchymal cells activates
p38 mitogen-activated protein kinase (MAPK) pathway,
increased production of TNF-α and led to the develop-
ment of inflammation in CDDP-injured kidneys [99]. Sev-
eral damage associated molecular patterns (DAMPs): heat
shock proteins (HSP)-60,-70, β-defensin-2, gp96 and
HMGB1, released from CDDP-injured PTECs, were desig-
nated as possible endogenous TLR-4 ligands capable to
initiate immune response in TLR-4:TNF-α-dependent
manner [99]. Additionally, CDDP-induced extensive re-
lease of endogenous TLR-4 ligands may activate inflam-
masome complex in renal infiltrated immune cells
resulting in enhanced production of inflammatory cyto-
kines (IL-1 and IL-18), further contributing to the devel-
opment of renal inflammation [100]. In line with these
findings, future experimental and clinical studies should
explore HMGB1, β-defensin-2, gp96, HSP-60 and 70 as
potential molecular targets for the TLR-4-related attenu-
ation of CDDP-caused AKI.
In addition to the activation of TLR-4 pathway, CDDP
treatment affects TLR-2 and TLR-9 signaling, as well.
Andrade-Silva and colleagues recently demonstrated that
TLR-2, opposite to TLR-4, protects against CDDP-induced
nephrotoxicity by promoting development of autophagy in
CDDP-injured renal cells [96]. Genetic deletion of TLR-2
down-regulated expression of autophagy-related genes in
PTECs which resulted in severe exacerbation of renal dys-
function and increased mortality rate of CDDP-treated
TLR-2 knockout animals [96]. Similarly as TLR-2, TLR-9
also plays renoprotective role in CDDP-caused nephrotox-
icity. As recently demonstrated by Alikhan and colleagues,
presence of immunosuppressive T regulatory cells (Tregs) in
CDDP-injured kidneys is, at least partially, regulated by
TLR-9 [101]. TLR-9 deficient mice had significantly reduced
number of Tregs in injured kidneys and consequently devel-
oped enhanced immune response and inflammation in
CDDP-injured kidneys [101]. Since TLR-9 responds to mito-
chondrial DAMPs [102], TLR-9-dependent expansion of
renal-infiltrated Tregs was probably elicited as a cytoprotec-
tive mechanism against CDDP-induced mitochondrial dam-
age. In line with these findings, specific delivery of TLR-2
and TLR-9 agonists in CDDP-injured PTECs and conse-
quent induction of autophagy and expansion of Tregs should
be tested in future experimental studies as new therapeutic
approach against CDDP-induced AKI.
Cytokine networking in CDDP-injured kidneys: a potential
target for renoprotection
Development and progression of renal inflammation
upon CDDP treatment is controlled and regulated by
complex interaction between inflammatory and im-
munosuppressive cytokines produced either by
CDDP-injured PTECs or renal-infiltrated immune cells
(Fig. 2). Among inflammatory cytokines, TNF-α appears to
play a central role in the inflammatory response triggered by
CDDP [103]. CDDP increases both serum and urine concen-
trations of TNF-α [103, 104], while CDDP-induced nephro-
toxicity was attenuated in TNF-α-deficient mice as well as in
mice treated with TNF-α inhibitors (pentoxifylline) or
TNF-α neutralizing antibodies [103]. Renal parenchymal
cells (mesangial cells, glomerular cells, endothelial and renal
tubular cells), macrophages and CD4+T helper lymphocytes
are cellular sources of TNF-α in CDDP-induced AKI [104].
Depletion of T cells reduced TNF-α production and pro-
tected against CDDP-induced AKI, suggesting crucial role of
T cells in TNF-α-driven renal inflammation elicited by
CDDP [104, 105]. Major role of TNF-α is to stimulate the
production of other inflammatory cytokines and chemokines
and to promote recruitment of inflammatory cells in
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CDDP-injured kidneys [93, 106–108]. Significant increase in
mRNA levels of macrophage inflammatory protein-2
(MIP-2), monocyte chemoattractant protein-1 (MCP-1),
IL-1β, and TGF-β has been observed in the kidneys of
CDDP-treated mice [109]. MIP-2, MCP-1 and IL-1β are in-
volved in recruitment of circulating monocytes in the in-
flamed renal parenchyma [110] while TGF-β has crucially
important role in the development of renal fibrosis [111]. Ac-
cordingly, an enhanced production of these inflammatory
mediators, further promoted TNF-α-driven AKI triggered by
CDDP. Importantly, production of MIP-2, MCP-1, IL-1β
and TGF-β in CDDP-injured kidneys was TNF-α-dependent
[109]. Selective inhibition of TNF-α significantly reduced
production of MIP-2, MCP-1, IL-1β, TGF-β and attenuated
AKI in CDDP-treated animals [109].
TNF-α induces expression of adhesion molecules on
renal endothelial cells and promotes influx of circulating
leucocytes in the inflamed renal parenchyma [112, 113].
Among selectins and integrins, intercellular adhesion
molecule-1 (ICAM-1) has shown to be the most important
for TNF-α-driven migration of immune cells into
CDDP-injured kidneys [114]. Accordingly, reduced infiltra-
tion of immune cells, accompanied with attenuated inflam-
mation and reduced PTECs damage correlated with
down-regulated expression of ICAM-1 and TNF receptors
(TNFR1–2) in CDDP-injured kidneys [115]. Although
TNFR1 was responsible for TNF-α-induced systemic and
anti-tumor effects [116], several lines of evidence demon-
strated that TNFR2 rather than TNFR1 mediates cytotoxic
and inflammatory actions of TNF-α in CDDP-injured
Fig. 2 Cell subtypes that play crucial role in the pathogenesis of cisplatin-induced AKI. Cisplatin-induced AKI involves the coordinated actions of
proximal tubular epithelial, endothelial, innate and adaptive immune cells. Abbreviations: ROS: Reactive oxygen species; IL: Interleukin; TNF-α:
Tumor necrosis factor alpha; MIF: Macrophage migration inhibitory factor; Mincle: Macrophage-inducible C-type lectin; CXCL1: Chemokine (C-X-C
motif) ligand 1; Kim-1: Kidney injury molecule-1; ICAM-1: Intercellular adhesion molecule-1
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kidneys [116, 117]. Compared to TNFR1 knockout mice,
TNFR2 deficient animals showed reduced serum and kid-
ney levels of TNF-α and were less susceptible to
CDDP-induced TNF-α-driven renal failure. Accordingly,
TNFR2 blockade should be evaluated in future experimen-
tal studies as potentially new therapeutic approach that
might reduce nephrotoxicity without affecting systemic and
anti-tumor effects of CDDP-induced TNF-α.
An increased concentration of TNF-α in CDDP-injured
kidneys was usually accompanied with significant elevation
of IL-8, IL-1β, and IL-18 in renal parenchyma of CDDP-
treated animals [118]. High renal concentration of these in-
flammatory cytokines further promoted TNF-α-driven in-
flammation and CDDP-induced renal failure [118]. Several
lines of evidence suggest that IL-8, in similar manner as
TNF-α, regulates ICAM-1-dependent influx of circulating
leukocytes in injured kidneys [119]. Administration of
α-melanocyte-stimulating hormone analogue, which inhib-
ited IL-8-dependent expression of ICAM-1, significantly re-
duced recruitment of inflammatory cells in the kidneys and
remarkably attenuated AKI [120].
Having in mind that IL-1β and IL-18 are synthesized
in inactive preforms and become activated in a
caspase-1 dependent manner [121, 122], caspase-1 was
designated as a potential molecular target for attenu-
ation of CDDP-induced nephrotoxicity. Faubel and co-
workers revealed that caspase-1 activity was remarkably
increased in the kidneys of CDDP-treated animals and
that renal dysfunction was significantly reduced in
caspase-1 deficient mice [123]. Moreover, genetic dele-
tion of caspase-1 significantly attenuated renal concen-
tration of IL-1β and IL-18 and reduced influx of
circulating neutrophils in CDDP-injured kidneys [123].
Interestingly, selective inhibition of IL-1β and IL-18 did
not alleviate CDDP-induced inflammation, suggesting
that other caspase-1-processed cytokines, also contrib-
uted to the progression of CDDP-caused AKI [118].
IL-1α, like IL-1β, is a pro-inflammatory cytokine which
initiates the same biological processes as IL-1β [124]. In
line with these findings, Lee and colleagues revealed an
important pathogenic role of IL-1α in the pathogenesis
of CDDP-induced nephrotoxicity and suggested that this
cytokine may be activated by caspase-1 during the pro-
gression of CDDP-caused inflammation [125]. Com-
pared with vehicle-treated mice, concentration of renal
IL-1α was significantly increased in CDDP-treated ani-
mals. Importantly, genetic deletion of IL-1α efficiently
protected against CDDP-induced AKI and the extent of
CDDP-caused renal injury was similar as it was observed
in caspase-1 deficient animals [125].
In addition to TNF-α, IL-1α-β, IL-8 and IL-18, re-
cently published studies indicated important role of
IL-17A and IL-33 in pathogenesis of CDDP-induced
AKI [126, 127]. An increased expression of IL-17A was
observed in CDDP-injured kidneys [127]. CDDP treat-
ment induces activation of inflammasome complex in
renal infiltrated leukocytes, resulting in extensive IL-17A
production. Innate immune cells (neutrophils and nat-
ural killer (NK) cells) were designated as the main
IL-17A producing cells in CDDP-induced nephrotoxicity
while IL-17A-producing T cells were not involved in
CDDP-caused renal inflammation since detrimental ef-
fects of IL-17A on renal structure and function were
also observed in RAR-related orphan receptor gamma T
(RORγT) deficient mice that lack effector CD4 + Th17
lymphocytes [127]. Administration of anti-IL-17A anti-
body efficiently protected against CDDP-induced nephro-
toxicity, confirming important pathogenic role of IL-17A
in CDDP-caused AKI [127].
IL-33 has the capacity to alter immune response elic-
ited in CDDP-injured kidneys [128]. Akcay and col-
leagues showed that IL-33 promotes inflammation in
CDDP-injured kidneys by acting as an alarmin [126].
IL-33, released from CDDP-injured PTECs, binds to
IL-33 receptor (ST2) on renal-infiltrated CD4+ T cells
and promotes secretion of inflammatory cytokines and
chemokines (particularly TNF-α and neutrophil chemo-
attractant CXCL1), contributing to the development of
acute renal inflammation [126]. In line with these obser-
vations, increased concentration of IL-33 was noticed in
sera and kidneys of CDDP-treated animals [126]. Im-
portantly, notably reduced acute tubular necrosis and
apoptosis was observed in mice treated with a soluble
IL-33 receptor (sST2), while administration of recom-
binant IL-33 (rIL-33) exacerbated CDDP-induced AKI
[126], indicating pro-inflammatory role of IL-33 in the
pathogenesis of CDDP-caused nephrotoxicity. Opposite
to these findings are results recently obtained by
Stremska and colleagues who demonstrated that two
subpopulations of renal-infiltrated immunosuppressive
and renoprotective cells (Tregs and innate lymphoid
cells, ILC) expressed ST2 receptor and extensively pro-
liferated in the presence of IL-2 and IL-33 [128]. In line
with these observations, Stremska and co-workers de-
signed IL-233, a novel IL-2 and IL-33 hybrid cytokine,
whose administration efficiently expanded ST2 express-
ing Tregs and ILCs in CDDP-injured kidneys and com-
pletely attenuated AKI and inflammation [128]. These
results strongly suggest nephroprotective potential of
IL-233 against CDDP-caused AKI which should be con-
firmed in future clinical trials.
Inflammatory cytokines and chemokines are exten-
sively produced in early phases of CDDP-induced AKI
[129]. Several lines of evidence suggested that elevation
in urine concentration of pro-inflammatory cytokines
and chemokines may be considered as an important par-
ameter for early diagnosis of CDDP-caused nephrotox-
icity. Increased levels of interferon γ-induced protein-10
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(IP-10), keratinocyte chemoattractant (KC) and
granulocyte-colony stimulating factor (G-CSF) were de-
tectable in the urine of CDDP-treated mice as early as 6
hours after treatment, long before the serum creatinine
or urea nitrogen levels were increased [22, 129]. Like-
wise, increased urinary levels of KC, IL-2, MCP-1,
GM-CSF and IL-8 were noticed in initial phase of
on-going renal inflammation in CDDP-treated dogs and
their concentration correlated with the progression of
renal dysfunction [130]. Accordingly, measurement of
urine levels of inflammatory mediators should be con-
sidered as an important approach for early diagnosis and
prevention of CDDP-induced nephrotoxicity [22].
Among anti-inflammatory and immunosuppressive cy-
tokines, it was well documented that IL-10, produced
mainly by renal-infiltrated Tregs and tolerogenic dendritic
cells, efficiently reduced CDDP-induced AKI and associ-
ated inflammation [131–133]. Soon after CDDP adminis-
tration, IL-10 producing Tregs migrated into injured
kidneys and suppressed detrimental TNF-α, IL-1 and
IL-17-driven immune response [134]. Antibody-mediated
depletion of endogenous Tregs leads to exacerbation of
CDDP-induced AKI, while their transfer protected against
CDDP-induced nephrotoxicity [134]. Adoptive transfer of
Tregs notably reduced production of inflammatory cyto-
kines (TNF-α and IL-1) in renal macrophages, suppressed
activation of IL-17-producing neutrophils and NK cells,
significantly attenuated inflammation and completely re-
stored renal function of CDDP-treated animals [134]. In
similar manner as Tregs, IL-10 producing tolerogenic
dendritic cells (DCs) have a protective role in
CDDP-induced AKI. DC-derived IL-10 inhibits produc-
tion of inflammatory cytokines in renal infiltrating T cells
and macrophages [114, 135–137]. Depletion of IL-10 pro-
ducing DCs significantly exacerbated CDDP-induced
nephrotoxicity while their passive transfer restored renal
function in CDDP-treated animals [135, 136]. In line with
these findings, cell-based therapy based on autologous
transplantation of IL-10 producing Tregs and tolerogenic
DCs in CDDP-injured kidneys should be further explored
as potentially new therapeutic approach for renoprotec-
tion of CDDP-treated patients.
In addition to IL-10, IL-6 had been also considered as
an important anti-inflammatory cytokine which may
protect against CDDP-induced nephrotoxicity [138]. Ad-
ministration of CDDP provoked increased production of
IL-6 in injured kidneys. An enhanced expression of IL-6
resulted in up-regulation of anti-oxidative enzymes in
inflamed renal parenchyma which prevented the devel-
opment of CDDP-caused renal dysfunction. In an ana-
logy, genetic deletion of IL-6 significantly reduced
activity of superoxide dismutase and increased expres-
sion of oxidative stress markers in CDDP-injured kid-
neys [138].
The impact of renal-infiltrated immune cells on the
development and progression of CDDP-induced AKI
CDDP treatment cause morphological and/or functional
changes in tubular and endothelial cells which leads to an in-
flux of mast cells, neutrophils, macrophages, NK cells and T
lymphocytes into the injured kidneys where these immune
cells play aggressive or protective role (Fig. 2).
Mast cells play an important pathogenic role in
CDDP-induced AKI. Selective depletion of mast cells attenu-
ated renal injury caused by CDDP, reduced recruitment of leu-
kocytes to the injured kidneys and notably down-regulated
serum levels of TNF-α, suggesting that mast cells mainly me-
diated CDDP-induced AKI in TNF-α-dependent manner
[139]. Mast cell-derived TNF-α and macrophage inflamma-
tory protein 2 (MIP-2) promote recruitment of neutrophils in
CDDP-injured kidneys significantly contributing to the aggra-
vation of on-going inflammation [140].
An increase in total number of renal infiltrated neutrophils
correlates with the extent of CDDP-induced AKI [141, 142].
Activated neutrophils, through the release of ROS, proteases,
and inflammatory cytokines cause tubular damage resulting
in extensive release of DAMPs and alarmins [143]. Signifi-
cant reduction of renal-infiltrated neutrophils can be
achieved by TNF-α inhibitors, TLR-4 antagonists or
anti-ICAM-1 antibodies [99, 115, 133, 144]. Nevertheless,
depletion of neutrophils was not enough to completely pro-
tect from CDDP-induced nephrotoxicity [135, 141], suggest-
ing that renal-infiltrating neutrophils are not the only effector
immune cells in the pathogenesis of AKI caused by CDDP.
Macrophages play an important pathogenic role in
CDDP-induced nephrotoxicity [145, 146]. An increased
number of macrophages was observed in injured kidneys
2 days after CDDP administration. CDDP induces acti-
vation of inflammasome, p38 MAPK and NF-kB path-
ways in renal macrophages resulting in increased
production of superoxide anions, nitric oxide (NO), IL-1
and TNF-α [106, 145]. It was recently revealed that
macrophage-inducible C-type lectin (Mincle), transmem-
brane pattern recognition receptor, is selectively expressed in
renal infiltrating M1 macrophages, and is responsible for
generation and maintenance of inflammatory phenotype of
these cells during CDDP induced AKI [146]. Mincle expres-
sion is regulated by TLR-4/NF-kB signaling pathway and its
down-regulation resulted in generation of nephroprotective,
alternatively activated macrophages whose adoptive transfer
efficiently protected against CDDP-induced nephrotoxicity
[146]. In line with these findings, Mincle represents a poten-
tial cellular target for alternative activation of renal macro-
phages in CDDP-treated patients and its nephroprotective
potential should be explored in future experimental and clin-
ical studies.
CD4+ Tcell deficient and, to a lesser extent, CD8-deficient
mice were less susceptible to CDDP-induced nephrotoxicity
compared with WTanimals, demonstrating importance of T
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lymphocytes in the pathogenesis of CDDP-induced nephro-
toxicity [104]. While CD4+ T helper cells in paracrine man-
ner (through the production of TNF-α, IL-17, IL-33 and
IL-10) orchestrate immune response in CDDP-injured kid-
neys, cytotoxic CD8+ T lymphocytes in juxtacrine, contact
dependent manner, induce damage of renal cells. CDDP
treatment increases expression of Fas receptors on renal
tubular cells enabling apoptosis of these cells due to their
interaction with FasL expressing renal infiltrating CD8+ T
lymphocytes [147]. CDDP induces enhanced expression of T
cell immunoglobulin mucin 1 (Tim-1) on PTECs [148]. Tim
1 acts as a costimulatory molecule playing important role in
activation of renal-infiltrated T cells [148]. Administration of
Tim-1-blocking antibody inhibited activation of renal-infil-
trated CD4+ helper and CD8+ cytotoxic T cells, reduced
apoptosis of PTECs and protected against CDDP-induced
AKI, indicating therapeutic and nephroprotective potential
of Tim-1 that should be further explored in up-coming ex-
perimental and clinical studies [148].
Conclusions
During the last decade, a large number of experimental stud-
ies have shed new light on molecular and cellular mecha-
nisms of CDDP-induced nephrotoxicity. Signaling pathways
which regulate cell survival, metabolism and immune re-
sponse are affected by CDDP. However, most of these path-
ways are, at the same time, crucially involved in cytotoxic
activity of CDDP against tumor cells and potential alterations
in their function might mitigate CDDP-induced anti-tumor
effects. Accordingly, despite the fact that many molecules
were designated as potential therapeutic targets for renopro-
tection against CDDP, modulation of CDDP-induced
nephrotoxicity is still a balance on the knife edge between
renoprotection and tumor toxicity. Design of new renopro-
tective strategies that would not limit CDDP-induced tumor-
icidal effects should rely on the identification of the
structural and functional differences between CDDP-injured
renal and tumor cells. Their implementation would open
new avenues in chemotherapy significantly enhancing clin-
ical utility of CDDP.
Abbreviations
AIF: Apoptosis-inducing factor; AKI: Acute kidney injury; AMPK: AMP-activated
protein kinase; APN: Aminopeptidase N; Atg5: Autophagy-related protein-5;
ATM: ataxia telangiectasia; ATP: Adenosine triphosphate; ATR: Rad3-related
protein; Bax: Bcl-2-associated X protein; Bcl-xL: B-cell lymphoma-extra large;
BER: base excision repair; BNP7787: disodium 2,2-dithio-bis-ethane sulfonate,
dimesna, Tavocept™; CCBL: cysteine-S-conjugate beta-lyase; CD: Cluster of
differentiation; CDDP: Cisplatin; CDK2: Cyclin-dependent kinase complex;
Chk2: Checkpoint kinase 2; Ctr: Copper transporter; CXCL1: Chemokine (C-X-C
motif) ligand 1; DAMPs: Damage associated molecular patterns;
DCs: Dendritic cells; DMTU: dimethylthiourea; DNA: Deoxyribonucleic acid;
ER: Endoplasmic reticulum; ER-iPLA2: Ca2+-independent phospholipase A2;
FasL: Fas ligand; FDA: Food and Drug Administration; GGT: Gamma glutamyl
transpeptidase; HMGB1: High mobility group box 1 protein; HNF-
1β: hepatocyte nuclear factor 1 homeobox B; HR: homologous
recombination; HSP: Heatschock protein; ICAM-1: Intercellular adhesion
molecule-1; IL: Interleukin; ILC: innate lymphoid cells; KIM-1: kidney injury
molecule-1; LC3: Microtubule-associated proteins 1A/1B light chain 3B;
MAPK: Mitogen-activated protein kinase; MATE1: Multidrug extrusion
transporter 1; Mincle: Macrophage-inducible C-type lectin; MIP-
2: Macrophage inflammatory protein 2; miR: microRNA; MLKL: Mixed lineage
kinase domain-like protein; mTOR: mammalian target of rapamycin;
NER: Nucleotide excision repair; NFkB: Nuclear factor kappa B; NK
cells: Natural killer cells; NO: Nitric oxide.; OCT2: Organic cation transporter 2;
PARP-1: poly ADP-ribose polymerase-1; PIDD: p53-induced protein with a
death domain; PTECs: proximal tubular epithelial cells; PUMA-α: p53
upregulated modulator of apoptosis; rIL-33: Recombinant interleukin-33;
RIP1: Receptor-interacting protein 1; RORγT: RAR-related orphan receptor
gamma T; ROS: Reactive oxygen species; SLC: Solute carrier family;
SNP: single-nucleotide polymorphism; TauT: Taurine transporter; TFF3: trefoil
factor 3; Tim-1: T cell immunoglobulin mucin 1; TLR: Toll like receptor;
TNFR: Tumor necrosis factor receptor; TNF-α: Tumor necrosis factor alpha;
Tregs: Regulatory T cells; WR2721: ethanethiol, 2-[(3-aminopropyl)amino]
dihydrogen phosphate ester; WT: Wild type
Funding
This study was supported by Serbian Ministry of Science (ON175069,
ON175103) and Faculty of Medical Sciences University of Kragujevac (MP 01/
18).
Availability of data and materials
Not applicable.
Authors’ contributions
VV: conception and design, manuscript writing; collection of data;
interpretation of data; BD: manuscript writing; collection of data; figure
creation; MGJ: manuscript writing; collection of data; CRH: manuscript writing
and editing; CF: manuscript writing and editing; VD: manuscript writing and
editing; NA: manuscript writing and editing. All authors read and approved
the final manuscript.





The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Center for Molecular Medicine and Stem Cell Research, Faculty of Medical
Sciences, University of Kragujevac, 69 Svetozar Markovic Street, Kragujevac
34000, Serbia. 2Department of Genetics, Faculty of Medical Sciences,
University of Kragujevac, Kragujevac, Serbia. 3Regenerative Processing Plant,
LLC, US Highway 19 N Palm Harbor, Palm Harbor, Florida 34176, USA.
4Institute of Anatomy, University of Bern, 2 Baltzerstrasse, Bern, Switzerland.
Received: 28 December 2018 Accepted: 7 March 2019
References
1. Cullen KJ, Yang Z, Schumaker L, Guo Z. Mitochondria as a critical target of
the chemotheraputic agent cisplatin in head and neck cancer. J Bioenerg
Biomembr. 2007;39:43–50. https://doi.org/10.1007/s10863-006-9059-5.
2. Vokes EE. Induction chemotherapy for head and neck cancer: recent data.
Oncologist. 2010;15(Suppl 3):3–7. https://doi.org/10.1634/theoncologist.
2010-S3-03.
3. Ilson DH. Esophageal Cancer chemotherapy: recent advances. Gastrointest
Cancer Res. 2008;2(2):85–92.
4. Ismaili N, Amzerin M, Flechon A. Chemotherapy in advanced bladder
cancer: current status and future. J Hematol Oncol. 2011;4:35. https://doi.
org/10.1186/1756-8722-4-35.
Volarevic et al. Journal of Biomedical Science           (2019) 26:25 Page 10 of 14
5. Chaudhary UB, Haldas JR. Long-term complications of chemotherapy for
germ cell tumours. Drugs. 2003;63(15):1565–77.
6. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al.
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus
intravenous cisplatin plus intravenous cyclophosphamide for stage III
ovarian cancer. N Engl J Med. 1996;335(26):1950–5.
7. Moxley KM, McMeekin DS. Endometrial carcinoma: a review of
chemotherapy, drug resistance, and the search for new agents. Oncologist.
2010;15(10):1026–33. https://doi.org/10.1634/theoncologist.2010-0087.
8. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et
al. Concurrent cisplatin-based radiotherapy and chemotherapy for
locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144–53.
https://doi.org/10.1056/NEJM199904153401502.
9. Gronwald J, Byrski T, Lubinski J, Narod SA. Cisplatin in breast cancer
treatment in BRCA1 carriers. Hered Cancer Clin Pract. 2012;10(Suppl 4):A17.
https://doi.org/10.1186/1897-4287-10-S4-A17.
10. KW L, Kim JH, Yun T, Song EK, Na II, Shin H, et al. Phase II study of low-dose
paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum
chemotherapy in gastric cancer. J Korean Med Sci. 2007;22(Suppl):S115–21.
https://doi.org/10.3346/jkms.2007.22.S.S115.
11. Zarogoulidis K, Zarogoulidis P, Darwiche K, et al. Treatment of non-small cell
lung cancer (NSCLC). J Thorac Dis. 2013;5(Suppl 4):S389–96. https://doi.org/
10.3978/j.issn.2072-1439.2013.07.10.
12. Chan BA, Coward JIG. Chemotherapy advances in small-cell lung cancer. J Thorac
Dis. 2013;5(Suppl 5):S565–78. https://doi.org/10.3978/j.issn.2072-1439.2013.07.43.
13. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of
action. Eur J Pharmacol. 2014;0:364–78. https://doi.org/10.1016/j.ejphar.2014.07.025.
14. Lucas D, Scheiermann C, Chow A, Kunisaki Y, Bruns I, Barrick C, et al.
Chemotherapy-induced bone marrow nerve injury impairs hematopoietic
regeneration. Nat Med. 2013;19(6):695–703. https://doi.org/10.1038/nm.3155.
15. Yamamoto H, Ishihara K, Takeda Y, Koizumi W, Ichikawa T. Changes in the
mucus barrier during cisplatin-induced intestinal mucositis in rats. Biomed
Res Int. 2013;2013:276186. https://doi.org/10.1155/2013/276186.
16. Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin
Pharmacother. 2003;4(6):889–901. https://doi.org/10.1517/14656566.4.6.889.
17. Kobayashi R, Suzuki A, Matsuura K, Yamada N, Nakano M, Deguchi T, et al.
Risk analysis for cisplatin-induced nephrotoxicity during first cycle of
chemotherapy. Int J Clin Exp Med. 2016;9(2):3635–41.
18. Tucker BM, Perazella MA. Medications. In: Lerma EV, Sparks MA, Topf J, editors.
Nephrology Secrets. 4th ed. Philadelphia, PA: Elsevier; 2018. p. 78–83.
19. Perazella MA. Onco-nephrology: renal toxicities of chemotherapeutic agents. Clin J
Am Soc Nephrol. 2012;7(10):1713–21. https://doi.org/10.2215/CJN.02780312.
20. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective
strategies. Kidney Int. 2008;73(9):994–1007. https://doi.org/10.1038/sj.ki.5002786.
21. Dos Santos NA, Carvalho Rodrigues MA, Martins NM, dos Santos AC. Cisplatin-
induced nephrotoxicity and targets of nephroprotection: an update. Arch
Toxicol. 2012;86(8):1233–50. https://doi.org/10.1007/s00204-012-0821-7.
22. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of
cisplatin nephrotoxicity. Toxins (Basel). 2010;2(11):2490–518. https://
doi.org/10.3390/toxins2112490.
23. Crona DJ, Faso A, Nishijima TF, McGraw KA, Galsky MD, Milowsky MI. A systematic
review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist. 2017;
22(5):609–19. https://doi.org/10.1634/theoncologist.2016-0319.
24. Hausheer FH, Parker AR, Petluru PN, Jair KW, Chen S, Huang Q, et al.
Mechanistic study of BNP7787-mediated cisplatin nephroprotection:
modulation of human aminopeptidase N. Cancer Chemother Pharmacol.
2011;67(2):381–91. https://doi.org/10.1007/s00280-010-1333-x.
25. Gandara DR, Wiebe VJ, Perez EA, Makuch RW, DeGregorio MW. Cisplatin
rescue therapy: experience with sodium thiosulfate, WR2721, and
diethyldithiocarbamate. Crit Rev Oncol Hematol. 1990;10(4):353–65.
26. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, et al. Amifostine
pretreatment for protection against cyclophosphamide-induced and
cisplatin-induced toxicities: results of a randomized control trial in patients
with advanced ovarian cancer. J Clin Oncol. 1996;14(7):2101–12.
27. Freyer DR, Chen L, Krailo MD, Knight K, Villaluna D, Bliss B, et al. Effects of
sodium thiosulfate versus observation on development of cisplatin-induced
hearing loss in children with cancer (ACCL0431): a multicentre, randomised,
controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18:63–74.
28. Hausheer FH, Kanter P, Cao S, Haridas K, Seetharamulu P, Reddy D, et al. Modulation
of platinum-induced toxicities and therapeutic index: mechanistic insights and first-
and second-generation protecting agents. Semin Oncol. 1998;25(5):584–99.
29. Fliedl L, Wieser M, Manhart G, Gerstl MP, Khan A, Grillari J, et al. Controversial
role of gamma-glutamyl transferase activity in cisplatin nephrotoxicity. ALTEX.
2014;31(3):269–78. doi: https://doi.org/10.14573/altex.1311152
30. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin
nephrotoxicity: a review. Am J Med Sci. 2007;334(2):115–24.
https://doi.org/10.1097/MAJ.0b013e31812dfe1e.
31. Bolisetty S, Traylor A, Joseph R, Zarjou A, Agarwal A. Proximal tubule-targeted
heme oxygenase-1 in cisplatin-induced acute kidney injury. Am J Physiol Renal
Physiol. 2016;310(5):F385–94. https://doi.org/10.1152/ajprenal.00335.2015.
32. Ciarimboli G. Membrane transporters as mediators of cisplatin side effects.
Anticancer Res. 2014;34(1):547–50.
33. Saito Y, Okamoto K, Kobayashi M, Narumi K, Furugen A, Yamada T, et
al. Magnesium co-administration decreases cisplatin-induced
nephrotoxicity in the multiple cisplatin administration. Life Sci. 2017;189:
18–22. https://doi.org/10.1016/j.lfs.2017.08.028.
34. Ciarimboli G, Deuster D, Knief A, et al. Organic cation transporter 2 mediates cisplatin-
induced Oto- and Nephrotoxicity and is a target for protective interventions. Am J
Pathol. 2010;176(3):1169–80. https://doi.org/10.2353/ajpath.2010.090610.
35. Nakamura T, Yonezawa A, Hashimoto S, Katsura T, Inui K. Disruption of
multidrug and toxin extrusion MATE1 potentiates cisplatin-induced
nephrotoxicity. Biochem Pharmacol. 2010;80(11):1762–7. https://doi.org/10.
1016/j.bcp.2010.08.019.
36. Nematbakhsh M, Ebrahimian S, Tooyserkani M, Eshraghi-Jazi F, Talebi A,
Ashrafi F. Gender difference in cisplatin-induced nephrotoxicity in a rat
model: greater intensity of damage in male than female. Nephrourol Mon.
2013;5(3):818–21. https://doi.org/10.5812/numonthly.10128.
37. Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A.
Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced
nephrotoxicity. Clin Pharmacol Ther. 2009;86(4):396–402. https://doi.org/10.
1038/clpt.2009.139.
38. Muraki K, Koyama R, Honma Y, Yagishita S, Shukuya T, Ohashi R, et al.
Hydration with magnesium and mannitol without furosemide prevents
the nephrotoxicity induced by cisplatin and pemetrexed in patients
with advanced non-small cell lung cancer. J Thorac Dis. 2012;4(6):562–8.
https://doi.org/10.3978/j.issn.2072-1439.2012.10.16.
39. Oka T, Kimura T, Suzumura T, Yoshimoto N, Nakai T, Yamamoto N, et al.
Magnesium supplementation and high volume hydration reduce the renal
toxicity caused by cisplatin-based chemotherapy in patients with lung
cancer: a toxicity study. BMC Pharmacol Toxicol. 2014;15:70. https://doi.org/
10.1186/2050-6511-15-70.
40. Yamamoto Y, Watanabe K, Tsukiyama I, Matsushita H, Yabushita H,
Matsuura K, et al. Nephroprotective effects of hydration with
magnesium in patients with cervical cancer receiving cisplatin.
Anticancer Res. 2015;35(4):2199–204.
41. Katsuda H, Yamashita M, Katsura H, Yu J, Waki Y, Nagata N, et al. Protecting
cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor
activity. Biol Pharm Bull. 2010;33(11):1867–71.
42. Pabla N, Murphy RF, Liu K, Dong Z. The copper transporter Ctr1 contributes to
cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol
Renal Physiol. 2009;296(3):F505–11. https://doi.org/10.1152/ajprenal.90545.2008.
43. Manohar S, Leung N. Cisplatin nephrotoxicity: a review of the literature. J
Nephrol. 2018;31(1):15–25. https://doi.org/10.1007/s40620-017-0392-z.
44. Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH. Metabolism of cisplatin
to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol. 2003;14(1):1–10.
45. Hanigan MH, Gallagher BC, Taylor PT Jr, Large MK. Inhibition of gamma-
glutamyl transpeptidase activity by acivicin in vivo protects the kidney from
cisplatin-induced toxicity. Cancer Res. 1994;54(22):5925–9.
46. Hanigan MH, Lykissa ED, Townsend DM, Ou CN, Barrios R, Lieberman MW.
Gamma-glutamyl transpeptidase-deficient mice are resistant to the
nephrotoxic effects of cisplatin. Am J Pathol. 2001;159(5):1889–94.
47. Daubeuf S, Balin D, Leroy P, Visvikis A. Different mechanisms for gamma-
glutamyltransferase-dependent resistance to carboplatin and cisplatin.
Biochem Pharmacol. 2003;66(4):595–604.
48. Paolicchi A, Sotiropuolou M, Perego P, Daubeuf S, Visvikis A, Lorenzini E, et
al. Gamma-Glutamyl transpeptidase catalyses the extracellular detoxification
of cisplatin in a human cell line derived from the proximal convoluted
tubule of the kidney. Eur J Cancer. 2003;39(7):996–1003.
49. George B, You D, Joy MS, Aleksunes LM. Xenobiotic transporters and kidney
injury. Adv Drug Deliv Rev. 2017;116:73–91.
50. Hausheer FH, Shanmugarajah D, Leverett BD, Chen X, Huang Q, Kochat H,
et al. Mechanistic study of BNP7787-mediated cisplatin nephroprotection:
Volarevic et al. Journal of Biomedical Science           (2019) 26:25 Page 11 of 14
modulation of gamma-glutamyl transpeptidase. Cancer Chemother
Pharmacol. 2010;65(5):941–51. https://doi.org/10.1007/s00280-009-1101-y.
51. Lieberthal W, Triaca V, Levine J. Mechanisms of death induced by
cisplatin in PTECs: apoptosis vs. necrosis. Am J Phys. 1996;270(4 Pt 2):
F700–8. https://doi.org/10.1152/ajprenal.1996.270.4.F700.
52. Lee RH, Song JM, Park MY, Kang SK, Kim YK, Jung JS. Cisplatin-induced
apoptosis by translocation of endogenous Bax in mouse collecting duct
cells. Biochem Pharmacol. 2001;62(8):1013–23.
53. Ozkok A, Edelstein CL. Pathophysiology of cisplatin-induced acute kidney
injury. Biomed Res Int. 2014;2014:967826. https://doi.org/10.1155/2014/967826.
54. Wei Q, Dong G, Franklin J, Dong Z. The pathological role of Bax in cisplatin
nephrotoxicity. Kidney Int. 2007;72(1):53–62. https://doi.org/10.1038/sj.ki.5002256.
55. Seth R, Yang C, Kaushal V, Shah SV, Kaushal GP. p53-dependent caspase-2
activation in mitochondrial release of apoptosis-inducing factor and its role
in renal tubular epithelial cell injury. J Biol Chem. 2005;280(35):31230–9.
https://doi.org/10.1074/jbc.M503305200.
56. Yin X, Apostolov EO, Shah SV, Wang X, Bogdanov KV, Buzder T, et al.
Induction of renal endonuclease G by cisplatin is reduced in DNase I-
deficient mice. J Am Soc Nephrol. 2007;18(9):2544–53. https://doi.org/10.
1681/ASN.2006080896.
57. Kaushal GP, Kaushal V, Hong X, Shah SV. Role and regulation of activation of
caspases in cisplatin-induced injury to renal tubular epithelial cells. Kidney
Int. 2001;60(5):1726–36. https://doi.org/10.1046/j.1523-1755.2001.00026.x.
58. Cummings BS, McHowat J, Schnellmann RG. Role of an endoplasmic reticulum Ca2
+−independent phospholipase A2 in cisplatin-induced renal cell apoptosis. J
Pharmacol Exp Ther. 2004;308(3):921–8. https://doi.org/10.1124/jpet.103.060541.
59. Liu H, Baliga R. Endoplasmic reticulum stress-associated caspase 12
mediates cisplatin-induced LLC-PK1 cell apoptosis. J Am Soc Nephrol. 2005;
16(7):1985–92. https://doi.org/10.1681/ASN.2004090768.
60. Boyce M, Yuan J. Cellular response to endoplasmic reticulum stress: a
matter of life or death. Cell Death Differ. 2006;13(3):363–73. https://doi.org/
10.1038/sj.cdd.4401817.
61. Anders HJ. Necroptosis in acute kidney injury. Nephron. 2018;139(4):342–8.
https://doi.org/10.1159/000489940.
62. Tristao VR, Goncalves PF, Dalboni MA, Batista MC, Durao Mde S Jr, Monte JC. Nec-1
protects against nonapoptotic cell death in cisplatin-induced kidney injury. Ren Fail.
2012;34(3):373–7. https://doi.org/10.3109/0886022X.2011.647343.
63. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat
Rev Drug Discov. 2005;4(4):307–20. https://doi.org/10.1038/nrd1691.
64. Kothandapani A, Dangeti VS, Brown AR, Banze LA, Wang XH, Sobol RW,
et al. Novel role of base excision repair in mediating cisplatin
cytotoxicity. J Biol Chem. 2011;286(16):14564–74. https://doi.org/10.1074/
jbc.M111.225375.
65. Basu A, Krishnamurthy S. Cellular responses to cisplatin-induced DNA
damage. J Nucleic Acids. 2010 Aug 8;2010. pii: 201367. doi: https://doi.org/
10.4061/2010/201367.
66. Hirama M, Isonishi S, Yasuda M, Ishikawa H. Characterization of
mitochondria in cisplatin-resistant human ovarian carcinoma cells. Oncol
Rep. 2006;16(5):997–1002.
67. Baliga R, Zhang Z, Baliga M, Ueda N, Shah SV. Role of cytochrome P-450 as
a source of catalytic iron in cisplatin-induced nephrotoxicity. Kidney Int.
1998;54(5):1562–9. https://doi.org/10.1046/j.1523-1755.1998.00161.x.
68. Durak I, Ozbek H, Karaayvaz M, Oztürk HS. Cisplatin induces acute renal
failure by impairing antioxidant system in Guinea pigs: effects of antioxidant
supplementation on the cisplatin nephrotoxicity. Drug Chem Toxicol. 2002;
25(1):1–8. https://doi.org/10.1081/DCT-100108468.
69. Appenroth D, Fröb S, Kersten L, Splinter FK, Winnefeld K. Protective effects
of vitamin E and C on cisplatin nephrotoxicity in developing rats. Arch
Toxicol. 1997;71(11):677–83.
70. Davis CA, Nick HS, Agarwal A. Manganese superoxide dismutase attenuates
cisplatin-induced renal injury: importance of superoxide. J Am Soc Nephrol.
2001;12(12):2683–90.
71. Yildirim Z, Sogut S, Odaci E, Iraz M, Ozyurt H, Kotuk M, Akyol O. Oral
erdosteine administration attenuates cisplatin-induced renal tubular
damage in rats. Pharmacol Res. 2003;47(2):149–56.
72. Jiang M, Dong Z. Regulation and pathological role of p53 in cisplatin
nephrotoxicity. J Pharmacol Exp Ther. 2008;327(2):300–7. https://doi.org/10.
1124/jpet.108.139162.
73. Jiang M, Wei Q, Wang J, Du Q, Yu J, Zhang L, Dong Z. Regulation of PUMA-
alpha by p53 in cisplatin-induced renal cell apoptosis. Oncogene. 2006;
25(29):4056–66. https://doi.org/10.1038/sj.onc.1209440.
74. Yang C, Kaushal V, Haun RS, Seth R, Shah SV, Kaushal GP. Transcriptional
activation of caspase-6 and -7 genes by cisplatin-induced p53 and its
functional significance in cisplatin nephrotoxicity. Cell Death Differ. 2008;
15(3):530–44. https://doi.org/10.1038/sj.cdd.4402287.
75. Han X, Chesney RW. Regulation of TauT by cisplatin in LLC-PK1 renal cells. Pediatr
Nephrol. 2005;20(8):1067–72. https://doi.org/10.1007/s00467-005-1887-8.
76. Zhou H, Fujigaki Y, Kato A, Miyaji T, Yasuda H, Tsuji T, et al. Inhibition of p21
modifies the response of cortical proximal tubules to cisplatin in rats. Am J Physiol
Renal Physiol. 2006;291(1):F225–35. https://doi.org/10.1152/ajprenal.00324.2004.
77. Price PM, Safirstein RL, Megyesi J. Protection of renal cells from cisplatin
toxicity by cell cycle inhibitors. Am J Physiol Renal Physiol. 2004;286(2):
F378–84. https://doi.org/10.1152/ajprenal.00192.2003.
78. Yu F, Megyesi J, Safirstein RL, Price PM. Identification of the functional
domain of p21(WAF1/CIP1) that protects cells from cisplatin cytotoxicity.
Am J Physiol Renal Physiol. 2005;289(3):F514–20. https://doi.org/10.1152/
ajprenal.00101.2005.
79. Yu F, Megyesi J, Safirstein RL, Price PM. Involvement of the CDK2-E2F1
pathway in cisplatin cytotoxicity in vitro and in vivo. Am J Physiol Renal
Physiol. 2007;293(1):F52–9. https://doi.org/10.1152/ajprenal.00119.2007.
80. Price PM, Yu F, Kaldis P, Aleem E, Nowak G, Safirstein RL, et al. Dependence
of cisplatin-induced cell death in vitro and in vivo on cyclin-dependent
kinase 2. J Am Soc Nephrol. 2006;17(9):2434–42. https://doi.org/10.1681/
ASN.2006020162.
81. Wei L, Chen W, Zou Y, Huang H, Pan B, Jin S, et al. AMP-activated protein kinase
regulates autophagic protection against cisplatin-induced tissue injury in the kidney.
Genet Mol Res. 2015;14(4):12006–15. https://doi.org/10.4238/2015.October.5.13.
82. Periyasamy-Thandavan S, Jiang M, Wei Q, Smith R, Yin XM, Dong Z.
Autophagy is cytoprotective during cisplatin injury of renal proximal tubular
cells. Kidney Int. 2008;74(5):631–40. https://doi.org/10.1038/ki.2008.214.
83. Takahashi A, Kimura T, Takabatake Y, Namba T, Kaimori J, Kitamura H, et al.
Autophagy guards against cisplatin-induced acute kidney injury. Am J
Pathol. 2012;180(2):517–25. https://doi.org/10.1016/j.ajpath.2011.11.001.
84. Yang C, Kaushal V, Shah SV, Kaushal GP. Autophagy is associated with
apoptosis in cisplatin injury to renal tubular epithelial cells. Am J Physiol Renal
Physiol. 2008;294(4):F777–87. https://doi.org/10.1152/ajprenal.00590.2007.
85. Jiang M, Wei Q, Dong G, Komatsu M, Su Y, Dong Z. Autophagy in proximal
tubules protects against acute kidney injury. Kidney Int. 2012;82(12):1271–83.
https://doi.org/10.1038/ki.2012.261.
86. Hao J, Lou Q, Wei Q, Mei S, Li L, Wu G, et al. MicroRNA-375 is induced in
cisplatin nephrotoxicity to repress hepatocyte nuclear factor 1-β. J Biol
Chem. 2017;292(11):4571–82. https://doi.org/10.1074/jbc.M116.754929.
87. Bhatt K, Zhou L, Mi QS, Huang S, She JX, Dong Z. MicroRNA-34a is induced
via p53 during cisplatin nephrotoxicity and contributes to cell survival. Mol
Med. 2010;16(9–10):409–16. https://doi.org/10.2119/molmed.2010.00002.
88. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS,
Chernov MV, et al. A chemical inhibitor of p53 that protects mice from the
side effects of cancer therapy. Science. 1999;285(5434):1733–7.
89. Tomasoni S, Benigni A. Gene therapy: how to target the kidney. Promises
and pitfalls Curr Gene Ther. 2004;4(1):115–22.
90. Tomita N, Azuma H, Kaneda Y, Ogihara T, Morishita R. Application of decoy
oligodeoxynucleotides-based approach to renal diseases. Curr Drug Targets.
2004;5(8):717–33.
91. Gudkov AV, Komarova EA. Prospective therapeutic applications of p53
inhibitors. Biochem Biophys Res Commun. 2005;331(3):726–36.
92. Perse M, Veceric-Haler Z. Cisplatin-Induced Rodent Model of Kidney Injury:
Characteristics and Challenges. Biomed Res Int. 2018;2018:1462802. https://
doi.org/10.1155/2018/1462802.
93. Ramesh G, Zhang B, Uematsu S, Akira S, Reeves WB. Endotoxin and cisplatin
synergistically induce renal dysfunction and cytokine production in mice. Am J Physiol
Renal Physiol. 2007;293(1):F325–32. https://doi.org/10.1152/ajprenal.00158.2007.
94. Mukhopadhyay P, Horváth B, Kechrid M, Tanchian G, Rajesh M, Naura AS, et
al. Poly (ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced
kidney inflammation and injury. Free Radic Biol Med. 2011;51(9):1774–88.
https://doi.org/10.1016/j.freeradbiomed.2011.08.006.
95. Kim J, Long KE, Tang K, Padanilam BJ. Poly (ADP-ribose) polymerase 1
activation is required for cisplatin nephrotoxicity. Kidney Int. 2012;82(2):193–
203. https://doi.org/10.1038/ki.2012.64.
96. Andrade-Silva M, Cenedeze MA, Perandini LA, Felizardo RJF, Watanabe IKM,
Agudelo JSH, et al. TLR2 and TLR4 play opposite role in autophagy
associated with cisplatin-induced acute kidney injury. Clin Sci (Lond). 2018;
132(16):1725–39. https://doi.org/10.1042/CS20170262.
Volarevic et al. Journal of Biomedical Science           (2019) 26:25 Page 12 of 14
97. Tsuboi N, Yoshikai Y, Matsuo S, Kikuchi T, Iwami K, Nagai Y, T et al. Roles of
toll-like receptors in C-C chemokine production by renal tubular epithelial
cells. J Immunol. 2002;169:2026–33.
98. Cenedeze MA, Gonçalves GM, Feitoza CQ, Wang PM, Damião MJ, Bertocchi AP,
et al. The role of toll-like receptor 4 in cisplatin-induced renal injury. Transplant
Proc. 2007;39(2):409–11. https://doi.org/10.1016/j.transproceed.2007.01.032.
99. Zhang B, Ramesh G, Uematsu S, Akira S. Reeves WB.TLR4 signaling mediates
inflammation and tissue injury in nephrotoxicity. J Am Soc Nephrol. 2008;
19(5):923–32. https://doi.org/10.1681/ASN.2007090982.
100. Zager RA, Johnson AC, Lund S, Hanson S. Acute renal failure: determinants
and characteristics of the injury-induced hyperinflammatory response. Am J
Physiol Renal Physiol. 2006;291:F546–56.
101. Alikhan MA, Summers SA, Gan PY, Chan AJ, Khouri MB, Ooi JD, Ghali JR, et al.
Endogenous toll-like receptor 9 regulates AKI by promoting regulatory T cell recruitment.
J Am Soc Nephrol. 2016;27(3):706–14. https://doi.org/10.1681/ASN.2014090927.
102. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, et al. Circulating
mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;
464(7285):104–7. https://doi.org/10.1038/nature08780.
103. Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine
expression and renal injury in cisplatin nephrotoxicity. J Clin Invest. 2002;
110(6):835–42. https://doi.org/10.1172/JCI15606.
104. Liu M, Chien CC, Burne-Taney M, Molls RR, Racusen LC, Colvin RB, et al. A
pathophysiologic role for T lymphocytes in murine acute cisplatin
nephrotoxicity. J Am Soc Nephrol. 2006;17(3):765–74. https://doi.org/10.
1681/ASN.2005010102.
105. Dong Z, Atherton SS. Tumor necrosis factor-alpha in cisplatin
nephrotoxicity: a homebred foe? Kidney Int. 2007;72(1):5–7. https://doi.org/
10.1038/sj.ki.5002320.
106. Ramesh G, Reeves WB. p38 MAP kinase inhibition ameliorates cisplatin
nephrotoxicity in mice. Am J Physiol Renal Physiol. 2005;289(1):F166–74.
https://doi.org/10.1152/ajprenal.00401.2004.
107. Ramesh G, Reeves WB. Cisplatin increases TNF-alpha mRNA stability in
kidney proximal tubule cells. Ren Fail. 2006;28(7):583–92. https://doi.org/10.
1080/08860220600843839.
108. Zhang B, Ramesh G, Norbury CC, Reeves WB. Cisplatin-induced
nephrotoxicity is mediated by tumor necrosis factor-alpha produced by
renal parenchymal cells. Kidney Int. 2007;72(1):37–44. https://doi.org/10.
1038/sj.ki.5002242.
109. Kumar P, Sulakhiya K, Barua CC, Mundhe N. TNF-α, IL-6 and IL-10
expressions, responsible for disparity in action of curcumin against cisplatin-
induced nephrotoxicity in rats. Mol Cell Biochem. 2017;431:113–22.
110. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation.
Nat Rev Immunol. 2011;11(11):762–74.
111. Choi ME, Ding Y, Kim SI. TGF-β signaling via TAK1 pathway: role in kidney
fibrosis. Semin Nephrol. 2012;32(3):244–52.
112. Summers SA, Chan J, Gan PY, Dewage L, Nozaki Y, Steinmetz OM, Nikolic-Paterson
DJ, Kitching AR, Holdsworth SR. Mast cells mediate acute kidney injury through the
production of TNF. J Am Soc Nephrol 201122(12):2226–2236.
113. Ramseyer VD, Garvin JL. Tumor necrosis factor-α: regulation of renal function
and blood pressure. Am J Physiol Renal Physiol. 2013;304(10):F1231–42.
114. Kelly KJ, Meehan SM, Colvin RB, Williams WW, Bonventre JV. Protection from
toxicant-mediated renal injury in the rat with anti-CD54 antibody. Kidney
Int. 1999;56(3):922–31. https://doi.org/10.1046/j.1523-1755.1999.00629.x.
115. Liu Y, Webb HK, Fukushima H, Micheli J, Markova S, Olson JL, Kroetz DL.
Attenuation of cisplatin-induced renal injury by inhibition of soluble
epoxide hydrolase involves nuclear factor κB signaling. J Pharmacol Exp
Ther. 2012;341(3):725–34. https://doi.org/10.1124/jpet.111.191247.
116. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor
superfamilies: integrating mammalian biology. Cell. 2001;104(4):487–501.
https://doi.org/10.1016/S0092-8674(01)00237-9.
117. Ramesh G, Reeves WB. TNFR2-mediated apoptosis and necrosis in cisplatin-
induced acute renal failure. Am J Physiol Renal Physiol. 2003;285(4):F610–8.
https://doi.org/10.1152/ajprenal.00101.2003.
118. Peres LA, da Cunha AD Jr. Acute nephrotoxicity of cisplatin: molecular
mechanisms. J Bras Nefrol. 2013;35(4):332–40.
119. Akcay A, Nguyen Q, Edelstein CL. Mediators of inflammation in acute kidney
injury. Mediat Inflamm. 2009;2009:137072.
120. Doi K, Hu X, Yuen PS, Leelahavanichkul A, Yasuda H, Kim SM, Schnermann J,
Jonassen TE, Frøkiaer J, Nielsen S, Star RA. AP214, an analogue of alpha-
melanocyte-stimulating hormone, ameliorates sepsis-induced acute kidney
injury and mortality. Kidney Int. 2008;73(11):1266–74.
121. Kuida K, Lippke JA, Ku G, Harding MW, Livingston DJ, Su MSS, Flavell RA.
Altered cytokine export and apoptosis in mice deficient in interleukin-1B
converting enzyme. Science. 1995;267:2000–2.
122. Li P, Allen H, Banerjee S, Franklin S, Herzog L, Johnston C, McDowell J,
Paskind M, Rodman L, Salfeld J. Mice deficient in IL-1 beta-converting
enzyme are defective in production of mature IL-1 beta and resistant to
endotoxic shock. Cell. 1995;80:401–11.
123. Faubel S, Ljubanovic D, Reznikov L, Somerset H, Dinarello CA, Edelstein CL.
Caspase-1-deficient mice are protected against cisplatin-induced apoptosis
and acute tubular necrosis. Kidney Int. 2004;66(6):2202–13.
124. Malik A, Kanneganti TD. Function and regulation of IL-1α in inflammatory
diseases and cancer. Immunol Rev. 2018;281(1):124–37.
125. Lee JW, Nam WJ, Han MJ, Shin JH, Kim JG, Kim SH, Kim HR, Oh DJ. Role of
IL-1α in cisplatin-induced acute renal failure in mice. Korean J Intern Med.
2011;26(2):187–94.
126. Akcay A, Nguyen Q, He Z, et al. IL-33 exacerbates acute kidney injury. J Am
Soc Nephrol. 2011;22(11):2057–67. https://doi.org/10.1681/ASN.2010091011.
127. Chan AJ, Alikhan MA, Odobasic D, Gan PY, Khouri MB, Steinmetz OM, et al.
Innate IL-17A-producing leukocytes promote acute kidney injury via
inflammasome and toll-like receptor activation. Am J Pathol. 2014;184(5):
1411–8. https://doi.org/10.1016/j.ajpath.2014.01.023.
128. Stremska ME, Jose S, Sabapathy V, Huang L, Bajwa A, Kinsey GR, et al. IL233,
A novel IL-2 and IL-33 hybrid cytokine, ameliorates renal injury. J Am Soc
Nephrol. 2017;28(9):2681–93. https://doi.org/10.1681/ASN.2016121272.
129. Zhang B, Ramesh G, Uematsu S, Akira S, Reeves WB. TLR4 signaling
mediates inflammation and tissue injury in nephrotoxicity. J Am Soc
Nephrol. 2008;19:923–32.
130. McDuffie JE, Sablad M, Ma J, Snook S. Urinary parameters predictive of
cisplatin-induced acute renal injury in dogs. Cytokine. 2010. https://doi.org/
10.1016/j.cyto.2010.06.005.
131. Tadagavadi RK, Reeves WB. Endogenous IL-10 attenuates cisplatin
nephrotoxicity: role of dendritic cells. J Immunol. 2010;185(8):4904–11.
https://doi.org/10.4049/jimmunol.1000383.
132. Deng J, Kohda Y, Chiao H, Wang Y, Hu X, Hewitt SM, et al. Interleukin-10
inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int. 2001;
60(6):2118–28. https://doi.org/10.1046/j.1523-1755.2001.00043.x.
133. Kim H, Lee H, Lee G, Jang H, Kim SS, Yoon H, et al. Phospholipase A2
inhibits cisplatin-induced acute kidney injury by modulating regulatory
T cells by the CD206 mannose receptor. Kidney Int. 2015;88(3):550–9.
https://doi.org/10.1038/ki.2015.147.
134. Lee H, Nho D, Chung HS, Lee H, Shin MK, Kim SH, et al. CD4+CD25+
regulatory T cells attenuate cisplatin-induced nephrotoxicity in mice. Kidney
Int. 2010;78(11):1100–9. https://doi.org/10.1038/ki.2010.139.
135. Tadagavadi RK, Gao G, Wang WW, Gonzalez MR, Reeves WB. Dendritic
cell protection from cisplatin nephrotoxicity is independent of
neutrophils. Toxins (Basel). 2015;7(8):3245–56. https://doi.org/10.3390/
toxins7083245.
136. Tadagavadi RK, Reeves WB. Renal dendritic cells ameliorate nephrotoxic
acute kidney injury. J Am Soc Nephrol. 2010;21(1):53–63. https://doi.org/10.
1681/ASN.2009040407.
137. Okusa MD, Li L. Dendritic cells in acute kidney injury: cues from the
microenvironment. Trans Am Clin Climatol Assoc. 2012;123:54–63.
138. Mitazaki S, Honma S, Suto M, Kato N, Hiraiwa K, Yoshida M, Abe S.
Interleukin-6 plays a protective role in development of cisplatin-induced
acute renal failure through upregulation of anti-oxidative stress factors. Life
Sci. 2011;88(25–26):1142–8.
139. Summers SA, Chan J, Gan P-Y, et al. Mast cells mediate acute kidney injury
through the production of TNF. J Am Soc Nephrol. 2011;22(12):2226–36.
https://doi.org/10.1681/ASN.2011020182.
140. Wang Y, Thorlacius H. Mast cell-derived tumour necrosis factor-alpha
mediates macrophage inflammatory protein-2-induced recruitment of
neutrophils in mice. Br J Pharmacol. 2005;145(8):1062–8. https://doi.org/10.
1038/sj.bjp.0706274.
141. Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, et
al. Cisplatin-induced acute renal failure is associated with an increase
in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil
infiltration in the kidney. J Pharmacol Exp Ther. 2007;322(1):8–15.
https://doi.org/10.1124/jpet.107.119792.
142. Deng B, Lin Y, Ma S, Zheng Y, Yang X, Li B, et al. The leukotriene B4-
leukotriene B4 receptor axis promotes cisplatin-induced acute kidney injury
by modulating neutrophil recruitment. Kidney Int. 2017;92(1):89–100.
Volarevic et al. Journal of Biomedical Science           (2019) 26:25 Page 13 of 14
143. Tadagavadi R, Reeves WB. Neutrophils in cisplatin AKI-mediator or marker?
Kidney Int. 2017;92(1):11–3. https://doi.org/10.1016/j.kint.2017.03.023.
144. Ramesh G, Reeves WB. Salicylate reduces cisplatin nephrotoxicity by
inhibition of tumor necrosis factor-alpha. Kidney Int. 2004;65(2):490–9.
https://doi.org/10.1111/j.1523-1755.2004.00413.x.
145. Tarang S, Sodhi A, Chauhan P. Differential expression of toll-like receptors in
murine peritoneal macrophages in vitro on treatment with cisplatin. Int
Immunol. 2007;19(5):635–43. https://doi.org/10.1093/intimm/dxm029.
146. Inoue T. M1 macrophage triggered by Mincle leads to a deterioration of acute
kidney injury. Kidney Int. 2017;91(3):526–9. https://doi.org/10.1016/j.kint.2016.11.026.
147. Jang HR, Rabb H. Immune cells in experimental acute kidney injury. Nat Rev
Nephrol. 2015;11(2):88–101. https://doi.org/10.1038/nrneph.2014.180.
148. Nozaki Y, Nikolic-Paterson DJ, Yagita H, Akiba H, Holdsworth SR, Kitching AR.
Tim-1 promotes cisplatin nephrotoxicity. Am J Physiol Renal Physiol. 2011;
301(5):F1098–104. https://doi.org/10.1152/ajprenal.00193.2011.
Volarevic et al. Journal of Biomedical Science           (2019) 26:25 Page 14 of 14
